Capricor’s Deramiocel Faces US Rejection After 9-3 AdComm Vote, Company Alleges Process Foul

FDA Adcomm Votes Against Capricor's DMD Therapy

Capricor Therapeutics' Duchenne muscular dystrophy cardiomyopathy drug, deramiocel, faced a significant setback after an FDA advisory committee voted 9-3 against its recommendation for approval. This decision caused Capricor's share value to plummet by nearly 80%. CEO Linda Marbán expressed strong concerns about the FDA's process, alleging "ulterior motives" and "biased intentions," particularly regarding the agency's focus on an outdated statistical analysis plan (SAP 1.1) over the most recent SAP 3.0. Marbán is open to collaborating with the FDA but is also considering legal action or pursuing approval outside the U.S. if no clear path forward is found before the August 22 action date.

• The FDA's Cellular, Tissue, and Gene Therapies Advisory Committee voted 9-3 against recommending Capricor's cell therapy, deramiocel, for Duchenne muscular dystrophy cardiomyopathy. This unexpected outcome caused Capricor's shares to plummet by nearly 80% immediately after the vote. CEO Linda Marbán criticized the FDA's approach, suggesting "ulterior motives" and "biased intentions," and stated she would explore legal action or international approval if a resolution with the agency isn't reached.
• A central point of contention was the FDA's reliance on an outdated statistical analysis plan (SAP 1.1) from the start of the HOPE-3 trial, rather than the most recently submitted SAP 3.0. Capricor argued that SAP 1.1 was an unsigned, incomplete draft that did not account for critical factors like intercurrent events or missing data, leading to non-statistically significant results in the FDA's analysis. In contrast, Capricor stated that all other SAP versions showed statistical significance.
• Patient advocates, including Mindy Leffler, echoed concerns about the FDA's analysis, citing "disingenuous things" that created misleading optics regarding the drug's efficacy. The press release also contextualizes this decision within recent regulatory friction in the broader Duchenne muscular dystrophy space, referencing issues with Sarepta's Elevidys and other exon skippers that received accelerated approval despite failed confirmatory trials, raising questions about consistency in the FDA's approach.

Disputed Data: How Endpoints Fueled the Adcomm Debate

Clinical studies in Duchenne muscular dystrophy (DMD) cardiomyopathy utilize a spectrum of endpoints, ranging from definitive clinical outcomes to functional assessments. Primary endpoints often include total mortality or a composite of death and heart failure hospitalization. Key secondary outcomes frequently involve changes in left ventricular ejection fraction (LVEF), serum natriuretic peptide levels such as BNP, and heart rate. LVEF is a cornerstone metric, serving not only as a primary measure of cardiac function—with a threshold of <55% often indicating dysfunction—but also as an inclusion criterion in some trials (e.g., LVEF ≤40%). Standard assessments have historically relied on electrocardiography and echocardiography, with techniques like Tissue Doppler imaging being particularly useful for the early detection of subtle myocardial damage and dysfunction.

To detect cardiomyopathy prior to overt functional decline, trials are increasingly employing advanced imaging and novel biomarkers. Cardiac magnetic resonance (CMR) is central to this effort, enabling quantification of myocardial fibrosis via late gadolinium enhancement (LGE) and extracellular volume (ECV), as well as inflammation or edema through T1 and T2 mapping. Functional analysis has evolved beyond LVEF to include sensitive strain-based metrics derived from feature tracking, MRI tagging, and 4D strain analysis. These include global longitudinal, circumferential, and radial strain (GLS, GCS, GRS), with studies reporting GCS values of -26.2% in DMD patients without LGE versus -30.0% in controls. Other early indicators include reduced mitral annular plane systolic excursion (MAPSE; 11.6 mm in patients vs 13.7 mm in controls), delays in peak systolic velocity timing (>60 ms), and ventricular dyssynchrony. Furthermore, changes in myocardial bioenergetics, measured by a reduced PCr/ATP ratio (1.59 in dystrophic hearts vs 2.37 in normal) using 31P magnetic resonance spectroscopy, serve as an early marker of metabolic dysfunction that can precede structural changes.

Why New Options for DMD Cardiomyopathy Face Tough Regulatory Terrain

Duchenne muscular dystrophy-associated cardiomyopathy (DMD-CM) remains a major driver of mortality, yet current treatment paradigms are hampered by diagnostic limitations, inconsistent guideline adherence, and a lack of definitive evidence to guide therapy. As respiratory care has improved patient survival, cardiac involvement has emerged as an increasingly prominent clinical challenge—one that existing regulatory and clinical frameworks are still struggling to address.

• Guideline adherence gap: An estimated 64% of DMD patients are not receiving recommended cardiac therapies, reflecting complex, systemic barriers to implementation rather than a single identifiable cause (2023).

• Exclusion from advanced heart failure therapies: Clinical and institutional barriers have historically excluded DMD patients from ventricular assist devices and heart transplantation, despite cardiomyopathy being a leading cause of death; these interventions remain rarely considered in this population (2026).

• Diagnostic and monitoring limitations: Standard heart failure metrics such as ejection fraction and symptom-based assessments have limited utility in DMD, and routine two-dimensional echocardiography is constrained by thoracic deformities and regional wall motion abnormalities common in this population (2014, 2026).

• Absence of curative or disease-modifying therapy: No treatment currently restores full-length dystrophin or halts disease progression; glucocorticoids prolong ambulation, while cardiac management remains largely symptomatic (2013, 2026).

• Lack of consensus on pharmacological management: While ACE inhibitors, angiotensin receptor blockers, beta-blockers, aldosterone antagonists, and angiotensin receptor–neprilysin inhibitors have shown promise in preserving left ventricular function and delaying DMD-CM progression, no consensus exists on optimal timing of initiation or DMD-specific treatment guidelines—management continues to be extrapolated from general heart failure frameworks (2005–2023).

• Rising disease burden amid improved survival: Improvements in musculoskeletal and respiratory care have extended patient lifespan, inadvertently increasing the incidence and clinical significance of cardiomyopathy, with cardiac-related deaths occurring in approximately 20% of DMD patients (2011, 2023).

• Emerging but unproven molecular approaches: Gene therapy, exon-skipping strategies, and interventions targeting mitochondrial dysfunction, calcium imbalance, and fibrosis show promising preclinical outcomes, alongside candidate agents such as tadalafil (PDE5 inhibition) and resveratrol (SIRT1 activation)—but none have yet translated into approved, disease-modifying clinical therapies (2015, 2018, 2026).

• Evidence gaps requiring larger, longer trials: Current data are insufficient to determine optimal intervention timing or long-term efficacy, underscoring the need for larger patient cohorts and extended follow-up to achieve statistically meaningful, clinically actionable conclusions (2011, 2018, 2023).

Deramiocel's Regulatory Roadblock in Duchenne Cardiomyopathy

The recent FDA advisory committee's decision regarding Capricor Therapeutics' deramiocel has sent ripples through the cell therapy community, particularly for those focused on Duchenne muscular dystrophy (DMD). While the company's allogeneic cardiosphere-derived cells (CDCs) showed promise in the HOPE-2 trial, demonstrating a reduction in the deterioration of upper limb function and improvements in cardiac measures in late-stage DMD patients, the committee's 9-3 vote against recommendation for approval highlights significant regulatory hurdles.

This outcome underscores the complex path for advanced cell therapies, especially when data interpretation, such as the dispute over statistical analysis plans (SAP 1.1 versus SAP 3.0), becomes a central point of contention. The literature supports the therapeutic potential of CDCs, noting their anti-fibrotic and immunomodulatory effects, often mediated by paracrine signaling through extracellular vesicles. Repeated intravenous dosing has also been identified as key to clinical success in DMD models. However, the journey for CDCs has not been without challenges, with some studies in other cardiac indications yielding mixed results or questioning their effectiveness.

For Capricor, the immediate strategic imperative is to meticulously address the FDA's concerns, potentially requiring a re-evaluation of their data presentation or even additional clinical work. The consideration of legal action or pursuing ex-U.S. approval pathways reflects the high stakes and the company's commitment to bringing this therapy to patients. Beyond deramiocel, this event serves as a reminder that while cell therapies hold immense promise for diseases like DMD, rigorous trial design, clear statistical methodologies, and robust regulatory engagement are paramount for successful translation from bench to bedside. The long-term future of regenerative medicine may also increasingly lean towards cell-free derivatives, leveraging the mechanistic insights gained from cell therapies to develop more scalable and potentially less complex treatments.